BFC Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.07M Buy
2,051
+95
+5% +$48.6K 0.04% 374
2026
Q2
$972K Buy
1,956
+58
+3% +$25.7K 0.04% 405
2026
Q1
$848K Buy
1,898
+111
+6% +$51.8K 0.04% 411
2025
Q4
$810K Buy
1,787
+1,348
+307% +$581K 0.04% 418
2025
Q3
$172K Buy
439
+4
+0.9% +$1.67K 0.01% 736
2025
Q2
$194K Buy
435
+61
+16% +$28.1K 0.02% 649
2025
Q1
$181K Buy
374
+68
+22% +$31.7K 0.02% 646
2024
Q4
$123K Buy
306
+72
+31% +$33.4K 0.01% 776
2024
Q3
$109K Buy
+234
New +$112K 0.01% 844

Other funds holding VRTX

BFC Planning's VRTX Position: Q3 2026 in Review

BFC Planning increased its Vertex Pharmaceuticals (VRTX) stake by 4.9% in Q3 2026, buying an estimated $48.6K and bringing the position to 2,051 shares worth $1.07M. The position accounts for 0.04% of the portfolio, ranked #374.

BFC Planning first reported a position in VRTX in Q3 2024 and has held it in 9 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • BFC Planning held 2,051 shares of Vertex Pharmaceuticals worth $1.07M as of Q3 2026.
  • BFC Planning bought 95 Vertex Pharmaceuticals shares in Q3 2026, an estimated $48.6K.
  • Vertex Pharmaceuticals made up 0.04% of BFC Planning's portfolio in Q3 2026, its #374 holding.
  • BFC Planning first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.